Novo Nordisk's Weekly Insulin Wins a Pediatric Label While the Buyback Ledger and a Trimmed Price Target Tell a Different Story

Novo Nordisk secured an expanded US label for its once-weekly basal insulin on Friday, but the regulatory win arrived alongside a more sobering read on the company's American business and a fresh snapshot of its capital-return machine.

The Food and Drug Administration cleared Awiqli for children aged ten and older with type 2 diabetes, widening a product that had previously been confined to adults. According to the agency, it is the first basal insulin dosed once a week for this patient group — cutting the injection burden from seven shots weekly to one. The approval is explicitly limited to pediatric type 2 diabetes, not to young diabetes patients across the board.

That distinction matters for anyone grading the announcement. Friday's decision broadens the approved use of an existing product; it does not, on its own, constitute evidence of improved financial performance.

A buyback running against a fixed ceiling

Separately, a mandatory disclosure filed on 19 October laid out where Novo Nordisk stands on its share repurchase plan. The program authorizes up to DKK 15 billion over twelve months starting 4 February 2026 — a ceiling, not a completed transaction. Through 16 October, the company had bought back 39,074,179 B shares for a total of DKK 10,875,024,304, per the filing with the US securities regulator.

The distinction between an authorization and its use is central here: the notice documents execution to date without announcing any expansion of the program. And while the buyback demonstrates how the company is deploying capital, it says nothing about whether revenue and earnings are heading in the right direction.

CagriSema's 25% figure comes with a caveat

Medical context arrived roughly a week earlier, when Novo Nordisk presented a post-hoc analysis of the REDEFINE 1 trial at the annual meeting of the Menopause Society. Among women, CagriSema was associated with an average weight loss of 25.0% after 68 weeks, against 3% on placebo. That 25% figure rested on the assumption that every patient adhered fully to treatment.

Unlike the Awiqli decision, this is a subgroup analysis within a clinical study — not a confirmed treatment outcome in routine care, and not a regulatory milestone. Investors would do well to keep the two categories of news apart.

BMO trims its target as US share erodes

A more cautious commercial view came from Evan Seigerman of BMO Capital on 12 October. According to media reports, he cut his price target to $40 from $47 while keeping a "Market Perform" rating. Seigerman pointed to a tough comparative base and shrinking US market share. He also flagged a prior-year effect of DKK 2 billion in the bridge from gross to net sales, which is expected to amplify the anticipated year-over-year decline in Ozempic in the third quarter of 2026.

The next scheduled checkpoint for testing those concerns is 4 November 2026, when Novo Nordisk reports results for the first nine months of the year, with a conference call to follow. Until then, the pediatric insulin approval stands as a concrete regulatory achievement — while whether the economic headwinds ease is a question that only the numbers can answer. Capital deployment, clinical data and operating results remain separate pieces of the valuation puzzle.